Daniel J. Lippis Sells 2,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Daniel J. Lippis sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Stock Performance

EW traded up $0.59 during trading on Monday, hitting $73.91. The company's stock had a trading volume of 5,992,934 shares, compared to its average volume of 4,648,238. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The business's 50 day simple moving average is $69.42 and its 200-day simple moving average is $73.90. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $43.59 billion, a PE ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same period last year, the firm earned $0.59 EPS. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp lifted its stake in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock valued at $1,733,270,000 after buying an additional 256,538 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company's stock worth $1,827,347,000 after buying an additional 809,605 shares during the period. Geode Capital Management LLC increased its stake in Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock worth $889,050,000 after buying an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock valued at $599,078,000 after acquiring an additional 806,705 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on EW shares. Stifel Nicolaus upped their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a "hold" rating in a research note on Thursday, December 5th. Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Wells Fargo & Company dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, September 9th. Morgan Stanley reissued an "equal weight" rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Piper Sandler decreased their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $79.40.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.